Why the study?
What is the prevalence of aspirin resistance in stroke patients receiving aspirin 300 mg/day for secondary prevention?
Population
291 stroke patients with first initiated aspirin therapy for secondary stroke prevention
Design
Cohort
Follow-up
1 year
Authors
Loading...
Aspirin non-response affects >11% on 300 mg; leaves open whether platelet monitoring improves stroke outcomes.
What is the prevalence of aspirin resistance in stroke patients receiving aspirin 300 mg/day for secondary prevention?
Aspirin resistance is not uncommon in stroke patients, with over 11% showing primary or secondary non-response to 300 mg/day, highlighting the potential need for platelet function monitoring.
Berrouschot et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: